Short Interest in Obsidian Therapeutics (NASDAQ:OBX) Grows By ∞

Posted by Lauren Steadman on Aug 31st, 2026

Obsidian Therapeutics (NASDAQ:OBX – Get Free Report) saw a large increase in short interest in the month of August. As of August 14th, there was short interest totaling 36,102 shares, an increase of ∞ from the July 30th total of 0 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily volume of 46,658 shares, the days-to-cover ratio is presently 0.8 days.

Wall Street Analyst Weigh In

OBX has been the topic of a number of research reports. Piper Sandler started coverage on shares of Obsidian Therapeutics in a research note on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 target price on the stock. TD Cowen started coverage on shares of Obsidian Therapeutics in a research note on Thursday, August 6th. They issued a “buy” rating for the company. Zacks Research raised shares of Obsidian Therapeutics to a “hold” rating in a research report on Thursday, August 6th. Finally, Lifesci Capital began coverage on Obsidian Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 price target for the company. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $42.50.

Read Our Latest Stock Analysis on OBX

Obsidian Therapeutics Stock Performance

Shares of NASDAQ OBX opened at $16.30 on Monday. Obsidian Therapeutics has a 12-month low of $14.57 and a 12-month high of $49.97.

Obsidian Therapeutics Company Profile

(Get Free Report)

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.